The HER2 Flip: HER2 Amplification of Tumor Cells in the Cerebrospinal Fluid (CSF-TCs) of Patients with Leptomeningeal Metastasis Having Solid Tumors; Implications for Treating the LM Tumor with Anti_HER2 Therapy BioceptNovember 22, 2022
Characterization of HER2 Amplification in the Cerebrospinal Fluid of Patients with Leptomeningeal Disease in Stage IV Patients with Breast Cancer San Antonio Breast Cancer Symposium 2021BioceptDecember 8, 2021
Case Series of Multi-Institutional Utility of CNSide™ to Manage Leptomeningeal Disease in Patients with Metastatic Breast Cancer BioceptNovember 25, 2021
HER2 Expression in Matched Metastatic Tumor and Circulating Tumor Cells (CTCs) In Breast Cancer: Implications for profiling and monitoring of HER2 status BioceptMarch 9, 2020
Clinical Utility of Target Selector™ Circulating Tumor Cell (CTC) Testing in Tumor Marker Gene Amplification and Protein Expression in Metastatic Breast Cancer Management BioceptMay 9, 2019
Monitoring breast cancer biomarkers from circulating tumor DNA using Target Selector™ NGS Breast Panel BioceptApril 9, 2019
Clinical Data in Over 1,500 Patients Across All Stages of Breast Cancer with Target Selector™ Circulating Tumor Cell Technology BioceptJanuary 9, 2019
Circulating Tumor Cell (CTC) Biomarker Evaluation from Patients with Metastatic Breast Cancer (MBC) Utilizing the Target Selector™ Platform BioceptApril 9, 2016
Correlation of hormone receptor status between circulating tumor cells, primary tumor and metastasis in breast cancer patients BioceptAugust 9, 2015
Prospective characterization of HER2-positive circulating tumor cells in patients with HER2- negative metastatic breast cancer BioceptMay 9, 2014
